Nicole Parrotta, APRN
Family · Grants Pass, ORNPI 1407231590
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,042 of the $3,028 with a category attached, or 67.4%. 30 manufacturers reported payments, led by Boston Scientific at 33.2% of the total. 2025 is the largest year on record at $1,005, 2.3 times the $443 reported in 2021. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $35.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- AbbVie$499
- Teva Pharmaceuticals USA, Inc.$312
- Acadia Pharmaceuticals Inc$216
- MDD US Operations, LLC$190
- EMD Serono, Inc.$121
- plus $686 from 24 others
What the payments were for
- Speaking & faculty fees$30610%
- Travel & lodging$68022%
- Food & beverage$2,04267%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $1,005 |
| AbbVie | 18 | $499 |
| Teva Pharmaceuticals USA, Inc. | 19 | $312 |
| Acadia Pharmaceuticals Inc | 8 | $216 |
| MDD US Operations, LLC | 2 | $190 |
| EMD Serono, Inc. | 1 | $121 |
| E.r. Squibb & Sons, L.L.C. | 1 | $93 |
| Sanofi | 5 | $88 |
| Acorda Therapeutics, Inc | 2 | $41 |
| Biogen | 2 | $40 |
| Biohaven Pharmaceuticals, Inc. | 2 | $39 |
| Johnson & Johnson | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $35 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| AstraZeneca | 1 | $23 |
| UCB, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Amgen | 1 | $21 |
| Argenx US, Inc. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $19 |
| Aquestive Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Novartis | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Cala Health, Inc. | 1 | $15 |
| Neurelis, Inc. | 1 | $15 |
| Upsher-smith Laboratories LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,028 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 14 | $20,736 |
| UbrelvyUbrogepant | 12 | $19,461 |
| Emgality PenGalcanezumab-Gnlm | 23 | $16,120 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 174 | $5,259 |
| Memantine Hcl | 92 | $3,890 |
| Donepezil Hcl | 201 | $2,819 |
| Levetiracetam | 78 | $2,412 |
| Sumatriptan Succinate | 43 | $1,219 |
| Gabapentin | 53 | $1,161 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 29 | $1,094 |
| AmantadineAmantadine Hcl | 17 | $1,087 |
| Divalproex Sodium | 44 | $1,051 |
| Propranolol Hcl | 44 | $994 |
| Eletriptan HbrEletriptan Hydrobromide | 11 | $979 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $940 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $15 | $20,73614 claims |
| AbbVieUbrelvy | $499 | $19,46112 claims |
| Upsher-smith Laboratories LLCTopiramate | $11 | $79463 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.
Other family in Grants Pass
- Laura JohnsonGrants Pass$3K
- Rachel PangilinanPortland$103K
- Jodeanna SweeneyCentral Point$45K
- Lani DoserPortland$45K
- David ArnopoleMedford$38K
- Heather HermanCorvallis$34K
- Amy BartramOregon City$33K
- Leah GaedekePortland$26K
- Bobbi Lee RothTualatin$23K
- Susan ToftePortland$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.